Shares rose 17.6% on strong revenue growth, margin expansion, and double-digit EPS growth that materially beat expectations, driven by broad-based strength across end markets and continued replacement cycle momentum.
- Reported $1.83 billion in revenue, up 6.3% core year-over-year, exceeding the high end of guidance by 80 basis points.
- Operating margin expanded 130 basis points year-over-year to 26.4%, surpassing guidance despite challenging macro and geopolitical conditions.
- EPS of $1.49 grew 14% year-over-year and topped guidance by $0.07.
- Balanced growth across key segments: Pharma +6%, Chemical & Advanced Materials +8%, Diagnostics & Clinical +11%, and Forensics over +50%, supported by significant new contracts and market share gains.
- Instrument revenue saw high single-digit growth with strong replacement cycle momentum and book-to-bill above 1 for the ninth consecutive quarter.
Community Discussion